Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Biosimilar Bill Prompts Formation of Nebraska Rheumatology Society

Kelly Tyrrell  |  March 1, 2018

He adds, “I think creating this avenue for a network will not only strengthen each of our own practices, but also the care for the patients in the state as a whole.”

Establishing a Network
To get the process started, Dr. Snow reached out to his contacts within the ACR for advice. Soon, he had more names than he could manage. The most pivotal suggestion he received was to partner with the Nebraska Medical Association.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“It has allowed all the technical aspects of forming a society to be dealt with by people who deal with those kinds of things,” he says. The association charges the rheumatology organization a small fee, covered by membership dues.

The biosimilar bill in Nebraska passed before the rheumatology society mobilized, and it’s one the organization is happy with, but Dr. Snow is grateful to now have a formal network in place to help engage the rheumatology community.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The legislature may be debating something at 2 p.m. on a Wednesday, and it can be tough to get out and [participate in the debate] if you’re in clinic,” he says. But now, “we can pool our resources to get someone there, to find people to testify, to communicate among ourselves.”


Kelly April Tyrrell writes about health, science and health policy. She lives in Madison, Wis.

Page: 1 2 | Single Page
Share: 

Filed under:Profiles Tagged with:Marcus SnowNebraska Rheumatology Societystate society

Related Articles
    Jennifer Elliott, MD

    The Nebraska Rheumatology Society Grows to Meet State’s Challenges

    May 15, 2020

    As state rheumatology societies go, the Nebraska Rheuma­tology Society (NRS) is one of the new kids on the block. Established two years ago, the NRS hopes to involve all 27 rheumatologists across the state. Marcus Snow, MD, a rheumatologist at the University of Nebraska Medical Center (UNMC), Omaha, says the state’s rheumatologists are spread across…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    January 19, 2018

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences